Dr. Cudkowicz is the Director of the Healey Center for ALS, Chief of Neurology at Mass General, and the Julieanne Dorn Professor at Harvard Medical School. On this advisory role at RockGen, Dr. Cudkowicz leverages over three decades of research and clinical activities in taking care of ALS patients and running clinical trials, therapeutic studies to stop ALS. She is one of the founders of the Northeast ALS Consortium and brought innovations to accelerate the development of treatments for people with ALS, including the first antisense oligonucleotide treatment for ALS and adaptive platform trial designs. Dr. Cudkowicz is Principal Investigator of the Clinical Coordination Center for the NINDS Neurology Network of Excellence in Clinical Trials. She is a member of AAP, NAM, and received the American Academy of Neurology Sheila Essay ALS award, the Pinnacle Award from the Boston Chamber of Commerce.
Dr. Kiaei is Associate Professor and leading ALS researcher with extensive experience in therapeutic development and pre-clinical drug discovery in neurodegenerative diseases. He has identified druggable targets for ALS and conducted therapeutic tests on promising drug candidates for ALS. As the founder of RockGen, he is dedicated to developing an effective drug for ALS and other neurodegenerative diseases. He leads the mission of RockGen and is deeply involved in the experimental design, implementation, and daily supervision of all aspects of the projects at RockGen.
Dr. Das is a Professor at the Long Island University in New York. He is adjunct faculty at Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai in New York.
He is a medicinal chemist and expert in pharmacological sciences. He has 28 patents and published 89 seminal scientific articles. Dr. Das's training background and experience started with postdoctoral training at MIT and Harvard Medical School and academic career experience at renowned institutions in the USA.